Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Navi Mumbai Drug Racket: Customs Superintendent, 2 Cops Among 10 Held; ₹ 73.9 Lakh Seized In US-Thailand Cartel Bust
Akshaya Tritiya 2025: Prayers, Charity And Gold Buying Mark Auspicious Day
Maharashtra State Cabinet Unveils EV Policy 2025 With Tax Waivers, Toll Exemptions And Infra Push
IPL 2025: Check Out The Points Table, Orange Cap & Purple Cap Holders After RR vs GT Match
